Pierre Feugier

Inserm — France

Medicine · Health Sciences

45h-index10.9kcitations184works3.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(163), Chronic Lymphocytic Leukemia Research(65), Viral-associated cancers and disorders(56), CAR-T cell therapy research(33), CNS Lymphoma Diagnosis and Treatment(20)

Publications183 total

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial
The Lancet·2025· 3 citedOpen Access
Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment
Blood·2025· 9 cited
44 | VALUE OF END OF INDUCTION MRD in ctDNA VERSUS PERIPHERAL BLOOD/BONE MARROW FOR EARLY RELAPSE PREDICTION IN ADVANCED FOLLICULAR LYMPHOMA: A RELEVANCE ANCILLARY STUDY
Hematological Oncology·2025Open Access
Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non‐Hodgkin lymphoma: Final analysis of a phase II trial from the <scp>LYSA</scp> group
British Journal of Haematology·2025· 1 citedOpen Access
Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study
Nature Cancer·2025· 16 citedOpen Access
Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma
Blood Advances·2025· 4 citedOpen Access
Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa
Blood·2024· 2 citedOpen Access
Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study
Blood·2024· 1 citedOpen Access
Health-Related Quality of Life after Axi-Cel As a Second-Line Therapy in Patients with High-Risk Relapsed/Refractory Large B-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Results of the Alycante Phase II Trial
Blood·2024
Prospective, Multicentric, Phase II Randomized Controlled Trial Comparing the Efficacy and Toxicity of Methotrexate to Cyclophosphamide in Large Granular Lymphocyte Leukemia: A French National Study (NCT01976182)
Blood·2024· 4 cited
Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase <scp>III</scp> trial of the European <scp>MCL</scp> Network
British Journal of Haematology·2024· 1 citedOpen Access
Author Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial
Nature Medicine·2024· 1 citedOpen Access
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma
Haematologica·2024· 3 citedOpen Access
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of &lt;i&gt;TP53&lt;/i&gt; mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
Haematologica·2023· 3 citedOpen Access
Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial
Journal of Clinical Oncology·2023· 14 citedOpen Access
Tislelizumab, an Anti-PD1 Antibody, in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma in Tirhol Bgb-A317-210: A Prospective Multicenter Lysa Phase 2 Study Conducted in Western Countries
Blood·2023· 1 citedOpen Access
Induction and Maintenance Therapy in Elderly Patients with Mantle Cell Lymphoma: Double-Randomized MCL R2 Elderly Clinical Trial By the European Mantle Cell Lymphoma Network
Blood·2023· 9 cited
Verlen, “Very Elderly Rituximab Associated to Lenalidomide - Tafasitamab Combination in Frontline DLBCL Patients”, a Phase II Open-Label Study Evaluating Efficacy of Lenalinomide and Tafasitamab Combination Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older from the Lysa Group
Blood·2023· 2 cited
Glofitamab Monotherapy in Patients with Non-Hodgkin B-Cell Lymphoma after Failing CAR T-Cell Infusion: Primary Analysis of the Bicar Study, a Phase II Lysa Study
Blood·2023· 15 cited
R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG
Blood·2023· 9 cited
page 1 of 10Next →

Frequent Co-authors

Gilles Salles(33), Corinne Haïoun(30), Olivier Casasnovas(24), Hervé Tilly(22), Catherine Thiéblemont(19), Franck Morschhauser(15), Bertrand Coiffier(14), Réda Bouabdallah(12), Luc Xerri(11), Pauline Brice(11), Vincent Ribrag(11), Olivier Hermine(10), Nicolas Mounier(10), Steven Le Gouill(9), Fritz Offner(8), Guillaume Cartron(8), Christian Gisselbrecht(7), Armando López‐Guillermo(7), Catherine Sebban(7), Eva Hoster(7)